Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 4/20 | 0.53 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.53 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.53 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.51 |
| ▸ | TP53 | P04637 | 2/20 | 0.51 |
| ▸ | TSHR | P16473 | 2/20 | 0.51 |
| ▸ | NPC1 | O15118 | 4/20 | 0.46 |
| ▸ | GAA | P10253 | 1/20 | 0.46 |
| ▸ | RAB9A | P51151 | 4/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.45 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.45 |
| ▸ | MAPT | P10636 | 1/20 | 0.45 |
| ▸ | FTO | Q9C0B1 | 2/20 | 0.44 |
| ▸ | ALKBH5 | Q6P6C2 | 1/20 | 0.44 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.43 |
| ▸ | PIP5K1C | O60331 | 1/20 | 0.43 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.43 |
| ▸ | PIK3CB | P42338 | 1/20 | 0.43 |
| ▸ | PI4KA | P42356 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29741763 | 1.00 | CYP3A4 (0.53) | CYP3A4CYP1A2CYP2C19SMN1; SMN2ALDH1A1 | |
| SCHEMBL21091211 | 0.93 | CYP3A4 (0.53) | CYP3A4CYP1A2CYP2C19SMN1; SMN2ALDH1A1 | |
| SCHEMBL9722790 | 0.86 | CYP3A4 (0.59) | CYP3A4CYP1A2CYP2C19SMN1; SMN2ALDH1A1 | |
| SCHEMBL31114638 | 0.86 | CYP3A4 (0.59) | CYP3A4CYP1A2CYP2C19SMN1; SMN2ALDH1A1 | |
| SCHEMBL14970154 | 0.81 | ALOX15 (0.62) | SMN1; SMN2ALDH1A1TP53TSHRNPC1 | |
| SCHEMBL21395441 | 0.81 | NPC1 (0.46) | ALDH1A1NPC1GAARAB9AKMT2A | |
| SCHEMBL11685051 | 0.81 | CYP3A4 (0.68) | CYP3A4CYP1A2CYP2C19SMN1; SMN2ALDH1A1 | |
| SCHEMBL2678487 | 0.80 | ILK (0.56) | CYP3A4CYP1A2CYP2C19SMN1; SMN2ALDH1A1 | |
| SCHEMBL6176142 | 0.80 | NPC1 (0.45) | ALDH1A1NPC1GAARAB9AKMT2A | |
| SCHEMBL5707550 | 0.80 | CYP3A4 (0.53) | CYP3A4CYP1A2CYP2C19SMN1; SMN2ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 71 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0039809-A2 | 2-Amino-5-halogen-benzothiazoles, process for preparing them and medicines containing them | Dr. Karl Thomae GmbH (DE) | 1981-11-18 | — | — | EP | claimed |
| US-12629356-B2 | Expansion of tumor infiltrating lymphocytes with potassium channel agonists and therapeutic uses thereof | IOVANCE BIOTHERAPEUTICS, INC. (US) | 2026-05-19 | — | — | US | disclosed |
| EP-3565586-B1 | EXPANSION OF TUMOR INFILTRATING LYMPHOCYTES WITH POTASSIUM CHANNEL AGONISTS AND THERAPEUTIC USES THEREOF | IOVANCE BIOTHERAPEUTICS INC (US) | 2025-10-08 | — | — | EP | disclosed |
| US-12024495-B2 | Benzothiazepine compounds and their use as bile acid modulators | ALBIREO AB (SE) | 2024-07-02 | — | — | US | disclosed |
| US-12024495-B2 | Benzothiazepine compounds and their use as bile acid modulators | ALBIREO AB (SE) | 2024-07-02 | — | — | US | disclosed |
| US-12024495-B2 | Benzothiazepine compounds and their use as bile acid modulators | ALBIREO AB (SE) | 2024-07-02 | — | — | US | disclosed |
| CN-112449637-B | Benzothiazepine compounds and their use as bile acid modulators | 阿尔比里奥公司 | 2024-03-19 | — | — | CN | disclosed |
| US-11773071-B2 | Benzothiazepine compounds and their use as bile acid modulators | ALBIREO AB (SE) | 2023-10-03 | — | — | US | disclosed |
| US-11773071-B2 | Benzothiazepine compounds and their use as bile acid modulators | ALBIREO AB (SE) | 2023-10-03 | — | — | US | disclosed |
| US-11773071-B2 | Benzothiazepine compounds and their use as bile acid modulators | ALBIREO AB (SE) | 2023-10-03 | — | — | US | disclosed |
| US-20160106754-A1 | USE OF CONDENSED BENZO[B]THIAZINE DERIVATIVES AS CYTOPROTECTANTS | ARANDA PHARMA LTD (FI) | 2016-04-21 | — | — | US | disclosed |
| EP-3004118-A1 | USE OF CONDENSED BENZO[B]THIAZINE DERIVATIVES AS CYTOPROTECTANTS | Aranda Pharma Ltd (FI) | 2016-04-13 | — | — | EP | disclosed |
| WO-2014191632-A1 | USE OF CONDENSED BENZO[B]THIAZINE DERIVATIVES AS CYTOPROTECTANTS | MEDEIA THERAPEUTICS LTD (FI) | 2014-12-04 | — | — | WO | disclosed |
| WO-2014191632-A1 | USE OF CONDENSED BENZO[B]THIAZINE DERIVATIVES AS CYTOPROTECTANTS | MEDEIA THERAPEUTICS LTD (FI) | 2014-12-04 | — | — | WO | disclosed |
| US-6465451-B1 | Hypolipidemic benzothiazepine compounds | SMITHKLINE BEECHAM CORPORATION | 2002-10-15 | — | — | US | disclosed |
| EP-1045840-A1 | HYPOLIPIDEMIC BENZOTHIAZEPINE COMPOUNDS | GLAXO GROUP LIMITED (GB) | 2000-10-25 | — | — | EP | disclosed |
| WO-1999035135-A1 | HYPOLIPIDEMIC BENZOTHIAZEPINE COMPOUNDS | GLAXO GROUP LIMITED (GB) | 1999-07-15 | — | — | WO | disclosed |
| EP-0039809-A3 | 2-AMINO-5-HALOGEN-BENZOTHIAZOLES, PROCESS FOR PREPARING THEM AND MEDICINES CONTAINING THEM | Dr. Karl Thomae GmbH (DE) | 1982-02-24 | — | — | EP | disclosed |
| EP-0039809-A2 | 2-Amino-5-halogen-benzothiazoles, process for preparing them and medicines containing them | Dr. Karl Thomae GmbH (DE) | 1981-11-18 | — | — | EP | disclosed |
| EP-0039809-A2 | 2-Amino-5-halogen-benzothiazoles, process for preparing them and medicines containing them | Dr. Karl Thomae GmbH (DE) | 1981-11-18 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160106754-A1 | USE OF CONDENSED BENZO[B]THIAZINE DERIVATIVES AS CYTOPROTECTANTS | TXN2, GPX4, NQO1 | CYP3A4 837/4885CYP1A2 580/4885CYP2C19 1105/4885 |
| US-11773071-B2 | Benzothiazepine compounds and their use as bile acid modulators | SLC10A1, SLC10A2, ABCB11 | CYP3A4 261/4885CYP1A2 292/4885CYP2C19 347/4885 |
| US-12024495-B2 | Benzothiazepine compounds and their use as bile acid modulators | SLC10A1, SLC10A2, ABCB11 | CYP3A4 261/4885CYP1A2 292/4885CYP2C19 347/4885 |
| US-12629356-B2 | Expansion of tumor infiltrating lymphocytes with potassium channel agonists and therapeutic uses thereof | PBK, IL2, KCNN3 | CYP3A4 3175/4885CYP1A2 2412/4885CYP2C19 3736/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.